Skip to main content

GlaxoSmithKline Enters Realm of Rare Diseases

By February 4, 2010December 18th, 2023Awareness, Science & Research

Following a path blazed by Genzyme and now followed by a number of other biotechs and pharmas,   Glaxo Smith Kline has announced they will be opening a division dedicated to finding medical treatments for rare diseases.

GSK has generously provided drug for the ongoing Children’s Tumor Foundation-funded Phase Zero trial to assess lapatinib as a candidate treatment for  NF2 vestibular schwannoma.  The new GSK rare disease program comes in the wake of other program closures at GSK.  We will watch this closely.